Adenine AMPK Activation for Glucose Uptake and ROS Reduction

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments and activators for AMP-activated protein kinase (AMPK) are limited in their efficacy and specificity for addressing various metabolic, inflammatory, and neurodegenerative diseases, as well as cancer, without effectively reducing COX-2 expression and ROS production.

Innovation Solution

Adenine is used as a novel AMPK activator to enhance phosphorylation of the AMPK subunit, thereby activating AMPK pathways to reduce COX-2 expression, increase glucose uptake, and inhibit ROS production, thus treating conditions such as diabetes, inflammation, neurodegeneration, and cancer.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing AMPK activators are used, then AMPK activation is achieved, but efficacy and specificity for addressing multiple diseases are limited

Engineering Contradiction:
ImproveAMPK activation efficacyVSAvoiddisease treatment coverage
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

Adenine is identified as a novel AMPK activator that demonstrates broad therapeutic potential across multiple disease categories including metabolic diseases (diabetes, obesity), inflammatory conditions, neurodegenerative diseases, and cancer. The compound activates AMPK to simultaneously address glucose metabolism, inflammation, oxidative stress, and cell proliferation, making it a universal agent for treating diverse pathological conditions.

Inventive Principle:
Principle #6Universality (Multi-functionality)

2Quantity of substance

If AMPK is activated to increase glucose uptake, then glucose levels decrease, but COX-2 expression and ROS production are not effectively reduced

Engineering Contradiction:
Improveglucose uptakeVSAvoidCOX-2 expression and ROS production
Core Design Contradiction:
Quantity of substanceVSObject-generated harmful factors

Solution Approach 1:

Adenine activates AMPK through phosphorylation at Thr172, inducing a conformational change that triggers multiple downstream signaling cascades. This parameter change in AMPK activation state simultaneously regulates glucose transporter translocation, COX-2 transcription, and ROS scavenging pathways, achieving coordinated reduction of glucose levels, COX-2 expression, and ROS production through a single molecular switch.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Adenine effectively activates AMPK, leading to significant reductions in glucose levels, inflammation, ROS production, and cancer cell proliferation, while enhancing wound healing and reducing scar formation.

Implementation Method 1

The activation of AMPK is through phosphorylation on the conserved 172th-threonine residue of α subunit by upstream kinases

Methodology Applied
Scientific EffectPhosphorylation: Chemical Bonding

Implementation Method 2

induces GLUT4 translocation to the plasma memberane in muscle cells in an insulin independent manner resulting in increases in the rate of cellular glucose uptake

Methodology Applied
Scientific EffectTranslocation: Diffusion

Implementation Method 3

Activation of AMPK can inhibit inflammation via suppressing NF-κB signaling. Several groups also demonstrate that activation of AMPK suppresses protein expression of cyclooxygenase-2 (COX-2)

Methodology Applied
Scientific EffectTranscriptional regulation: Enzyme

Implementation Method 4

activation of AMPK induces autophagy via suppressing mTORC1 activity. Due to the inhibition of mTORC1 by AMPK, phosphorylation of Ulk1 on Ser757 is decreased and subsequently Ulk1 can be phosphorylated by AMPK on Ser757 and Ser. The AMPK-phosphorylated Ulk1 is active and then initiates autophagy

Methodology Applied
Scientific EffectPhosphorylation: Chemical Bonding

Data Source

PatentUS20260069597A1Method for activating AMPK and the use of adenine
Publication Date: 2026.03.12 ENERGENESIS BIOMEDICAL CO LTD

AI summary

The present invention relates to adenine which is useful to activate AMP-activated protein kinase (AMPK) and the use of adenine in the prevention or treatment of conditions or disease and thereby prevent or treat conditions or diseases which can be ameliorated by AMPK in a mammal.